Cerebral infarction

There are 281 papers on cerebral infarction in aging research: 3 trials and 230 observational studies in people, 28 in animals, 1 in cells, 16 reviews. The newest story, Nov 9, 2026: “Obesity linked to lower stroke risk in heart rhythm study”.

Disease

281 papers study it100 more mention it73 findings

MeSH

30 new papers in 30 daysSee all 381 papers on cerebral infarction

“the Low-smoking active group had lower odds of cerebral infarction (OR 0.88, 95% CI 0.84, 0.92).”
Associations of multi-trajectories of smoking, alcohol use, and physical activity with cardiovascular and cerebrovascular disease risk in Korean adults: A nationwide matched case-control studyPreventive medicine2026doi:10.1016/j.ypmed.2026.108685
  • Human trial3
  • Humans230
  • Animals28
  • Cells1
  • In silico1

Interventions

12

PCSK9 inhibitors

no changein humans1

1 study
  1. PCSK9 inhibitors were not clearly linked with cerebral infarction in humans (Primary prevention chronic kidney disease; compared with statin therapy) (0.6% vs 0.5%; p=0.094).

    “There was no significant difference in the risk of cerebral infarction (0.6% vs 0.5%, p=0.094)”

    HumansPrimary prevention chronic kidney disease; compared with statin therapyThree-year follow-up

    Proprotein Convertase Subtilisin/Kexin 9 Inhibitors versus Statins in Chronic Kidney Disease: A Propensity-Matched Analysis

    AHA Scientific Sessions 2026 abstract

More on PCSK9 inhibitors

GLP-1 receptor agonists + SGLT2 inhibitors

no changein humans1

1 study
  1. GLP-1 receptor agonists + SGLT2 inhibitors were not clearly linked with cerebral infarction in humans.

    “No significant differences were observed for myocardial infarction, cerebral infarction, or end-stage renal disease.”

    HumansHeart transplant recipients with type 2 diabetes mellitus and/or BMI ≥35 kg/m 2; compared with SGLT2 inhibitor therapy aloneUp to 3 yearsn = 256

    Peri-Transplant SGLT2 Inhibitor Plus GLP-1 Receptor Agonist Therapy versus SGLT2 Inhibitor Therapy Alone and Outcomes After Heart Transplantation in Patients with Type 2 Diabetes Mellitus and/or BMI ≥35 kg/m ²

    AHA Scientific Sessions 2026 abstract

More on GLP-1 receptor agonists + SGLT2 inhibitors

Aortic valve replacement

no changein humans1HR 1.01

1 study
  1. Aortic valve replacement was not clearly linked with cerebral infarction in humans (aortic stenosis) (HR 1.01, 95% CI 0.96-1.05).

    “cerebral infarction (HR 1.01, 95% CI 0.96-1.05)”

    Humansaortic stenosis

    Aortic valve replacement linked to lower dementia risk

    ESC Congress 2026 abstract

More on Aortic valve replacement

Catheter ablation

no changein humans1

1 study
  1. Catheter ablation was not clearly linked with cerebral infarction in humans (patients with atrial fibrillation undergoing ablation).

    “No new cerebral infarcts were detected after ablation.”

    Humanspatients with atrial fibrillation undergoing ablationbrainwithin 48 hoursn = 75

    Global and Domain-Specific Cognitive Outcomes After Catheter Ablation for Atrial Fibrillation

    JAMA network open

More on Catheter ablation

Tirzepatide

downin humans1HR 0.733

1 study
  1. Tirzepatide is linked with lower cerebral infarction in humans (versus semaglutide, in type 2 diabetic adults after CABG) (HR 0.733 (95% CI 0.580-0.927); 5.1% vs 7.5%).

    “Superior cerebrovascular protection with tirzepatide was also seen at 6 months following CABG with lower rates of cerebral infarction (5.1% vs. 7.5%, HR=0.733, 95%CI=0.580-0.927, p=0.001)”

    Humansversus semaglutide, in type 2 diabetic adults after CABG6 monthsn = 3,667

    The Effect of Tirzepatide versus Semaglutide on Post-Operative Outcomes in Type 2 Diabetics Following Coronary Artery Bypass Grafting

    AHA Scientific Sessions 2025 abstract

More on Tirzepatide

Butylphthalide

downin mice1

1 study
  1. Butylphthalide decreases cerebral infarction in mice within 4 h after t-MCAO/R.

    “Intraperitoneal injection of NBP within 4 h or intravenous injection of NAD+ within 1 h after t-MCAO/R significantly reduced the volume of infarcts, cerebral edema, and neurological deficits.”

    Animalswithin 4 h after t-MCAO/Rbrain

    Neuroprotection of NAD⁺ and NBP against ischemia/reperfusion brain injury is associated with restoration of sirtuin-regulated metabolic homeostasis

    Frontiers in pharmacology

More on Butylphthalide

Nicotinamide adenine dinucleotide

downin mice1

1 study
  1. Nicotinamide adenine dinucleotide decreases cerebral infarction in mice within 1 h after t-MCAO/R.

    “intravenous injection of NAD+ within 1 h after t-MCAO/R significantly reduced the volume of infarcts, cerebral edema, and neurological deficits.”

    Animalswithin 1 h after t-MCAO/Rbrain

    Neuroprotection of NAD⁺ and NBP against ischemia/reperfusion brain injury is associated with restoration of sirtuin-regulated metabolic homeostasis

    Frontiers in pharmacology

More on Nicotinamide adenine dinucleotide

Nicotinamide mononucleotide

downin mice1

1 study
  1. Nicotinamide mononucleotide decreases cerebral infarction in mice (MCAO mice).

    “NMN reduced cerebral infarction at 24 h post-MCAO.”

    AnimalsMCAO mice300 mg/kg intravenous24 h post-MCAO

    Distribution of Nicotinamide Mononucleotide after Intravenous Injection in Normal and Ischemic Stroke Mice

    Current pharmaceutical biotechnology

More on Nicotinamide mononucleotide

Atorvastatin

downin humans1

1 study
  1. Atorvastatin decreases cerebral infarction in humans after aneurysmal subarachnoid hemorrhage (18.7% vs 27.3%, P=0.027).

    “The incidence of postoperative cerebral vasospasm (39.3% vs 56%, P =0.004) and cerebral infarction (18.7% vs 27.3%, P=0.027) were significantly lower in the atorvastatin group”

    Human trialafter aneurysmal subarachnoid hemorrhage20 mg/dayup to 14 days

    Atorvastatin reduces cerebral vasospasm and infarction after aneurysmal subarachnoid hemorrhage in elderly Chinese adults

    Aging

More on Atorvastatin

Melatonin

downin rats1

1 study
  1. Melatonin protects against cerebral infarction in rats after MCA occlusion in 18-month-old rats.

    “melatonin acted as a valuable therapeutic agent protecting aged animals from the harmful effects of cerebral infarction”

    Animalsafter MCA occlusion in 18-month-old rats

    Comparison of the Effect of Melatonin Treatment before and after Brain Ischemic Injury in the Inflammatory and Apoptotic Response in Aged Rats

    International journal of molecular sciences

More on Melatonin

All 12

Effects

2

CREBBP

upin cells1

1 study
  1. Cerebral infarction increases CREBBP in an in vitro model of cerebral infarction.

    “our results demonstrate that the expression of these genes and proteins at these core targets are elevated to varying degrees in an in vitro model of cerebral infarction”

    Cellsin an in vitro model of cerebral infarction

    Treatment targets of cellular senescence and circadian rhythms in ischemic stroke

    Medicine

More on CREBBP

Brain age

upin humans1

1 study
  1. Cerebral infarction is linked with higher brain age in humans (compared to individuals without infarcts) (approximate 5-year increase).

    “The presence of infarct(s) was associated with lower total brain volumes, which was equal to an approximate 5-year increase in brain aging compared to individuals without infarcts.”

    Humanscompared to individuals without infarctsbrainn = 1,886

    Cardiovascular disease risk exacerbates brain aging among Hispanic/Latino adults in the SOL-INCA-MRI Study

    Frontiers in aging neuroscience

More on Brain age

Associations

52

SGLT2 inhibitors

downin humans3RR 0.866

3 studies
  1. SGLT2 inhibitors are associated with cerebral infarction in humans (Hypertension and obesity; add-on therapy compared with antihypertensive therapy alone) (4.6% vs 5.3%; RR 0.866, 95% CI 0.832–0.902; time-to-event HR 0.960, 95% CI 0.921–1.001).

    “SGLT2i cohort was associated with significantly lower risk of cerebral infarction”

    HumansHypertension and obesity; add-on therapy compared with antihypertensive therapy aloneMean follow-up 3.6–4.2 years

    Add-ons linked to fewer strokes in treated hypertension with obesity

    AHA Scientific Sessions 2026 abstract

  2. SGLT2 inhibitors are associated with cerebral infarction in humans (Type 2 diabetes; compared with DPP-4 inhibitors after propensity score matching) (3.2% vs 3.7%; HR 0.783, 95% CI 0.761–0.806).

    “Cardiovascular benefits included lower cerebral infarction (3.2% vs 3.7%; risk ratio 0.858, 95% CI 0.834-0.882; HR 0.783, 95% CI 0.761-0.806)”

    HumansType 2 diabetes; compared with DPP-4 inhibitors after propensity score matching5 years

    Comparative Cardiovascular Outcomes of SGLT2 Inhibitors versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

    AHA Scientific Sessions 2026 abstract

  3. SGLT2 inhibitors are linked with a lower risk of cerebral infarction in humans (type 2 diabetes) (adjusted hazard ratio=0.84, p=0.010).

    “SGLT2 inhibitor users showed lower recurrence of cerebral infarction compared to metformin users (adjusted hazard ratio=0.84, p=0.010).”

    Humanstype 2 diabetes

    Association between SGLT2 inhibitors and recurrence of cerebrovascular events in patients with type 2 diabetes: A population-based cohort study

    Diabetes & vascular disease research

More on SGLT2 inhibitors

Mild cognitive impairment

upin humans3HR 1.51

3 studies
  1. Cerebral infarction is associated with mild cognitive impairment in humans (Multivariable-adjusted analysis).

    “cerebral infarction was associated with an increased risk of MCI, lower MoCA total scores, and higher GDS total scores (all P<0.01).”

    HumansMultivariable-adjusted analysisn = 2,188

    A study of the association of the number of vascular-metabolic comorbidities with cognitive function and depression among community-dwelling older adults in Shanghai

    Geriatrics & Health Care

  2. Cerebral infarction is linked with a higher risk of mild cognitive impairment in humans (HR = 1.51, p = 0.007).

    “and cerebral infarction (HR = 1.51, p = 0.007)”

    Humans

    Modifiable Risk Factors for Mild Cognitive Impairment in Elderly Populations: Insights from a Shanghai Community Cohort Study

    AAIC 2025 abstract

  3. Cerebral infarction is linked with a higher risk of mild cognitive impairment in humans (adjusted RR=1.49 (95% CI: 1.05-2.12)).

    “with history of cerebral infarction (adjusted RR=1.49; 95% CI: 1.05-2.12), history of cerebral hemorrhage (adjusted RR=3.20; 95% CI: 1.22-8.40) were found to have significantly higher risk of MCI.”

    Humans2 yearsn = 985

    Incidence and risk factors associated with progression to mild cognitive impairment among middle aged and older adults

    European review for medical and pharmacological sciences

More on Mild cognitive impairment

GLP-1 receptor agonists

downin humans2HR 0.936

2 studies
  1. GLP-1 receptor agonists are associated with cerebral infarction in humans (Hypertension and obesity; add-on therapy compared with antihypertensive therapy alone) (3.4% vs 4.0%; HR 0.936, 95% CI 0.900–0.973).

    “GLP-1 RA add-on therapy was associated with significantly lower risk of cerebral infarction”

    HumansHypertension and obesity; add-on therapy compared with antihypertensive therapy aloneMean follow-up 3.6–4.2 years

    Add-ons linked to fewer strokes in treated hypertension with obesity

    AHA Scientific Sessions 2026 abstract

  2. GLP-1 receptor agonists are associated with cerebral infarction in humans (Type 2 diabetes mellitus; compared with SGLT2 inhibitors) (4.8% vs 6.3%; RR 0.77, HR 0.73).

    “GLP-1 RA therapy was associated with significantly lower risks of all evaluated outcomes compared with SGLT2 inhibitors.”

    HumansType 2 diabetes mellitus; compared with SGLT2 inhibitors

    Comparative Cardiovascular and Mortality Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study

    AHA Scientific Sessions 2026 abstract

More on GLP-1 receptor agonists

Vascular dementia

upin humans2

2 studies
  1. Cerebral infarction is associated with vascular dementia in humans (early pre-diagnosis).

    “while VaD was characterized by early cerebral infarctions, type 1 diabetes, intestinal disorders, and rheumatoid arthritis, absent in controls.”

    Humansearly pre-diagnosis

    Temporal comorbidity patterns in Alzheimer's disease and vascular dementia: A population-based observational study in UK Biobank

    Alzheimer's & dementia (Amsterdam, Netherlands)

  2. Cerebral infarction is associated with vascular dementia in humans (up to 20 years before diagnosis).

    “Circulatory diseases, including cerebral infarctions were consistently associated with Vascular Dementia, up to 20 years before diagnosis.”

    Humansup to 20 years before diagnosisup to 20 years

    Chronological Patterns of Comorbidities in Alzheimer's Disease and Vascular Dementia: A Longitudinal Network Analysis

    AAIC 2025 abstract

More on Vascular dementia

Diabetes mellitus

upin humans2OR 1.43

2 studies
  1. Diabetes mellitus is associated with cerebral infarction in humans (OR=1.43; 95% CI, 1.07-1.90).

    “Diabetes was associated with a higher odds of any infarct (OR=1.43; 95% CI, 1.07-1.90)”

    Humansbrainn = 1,228

    Diabetes, Hemoglobin A1C, and Regional Alzheimer Disease and Infarct Pathology

    Alzheimer disease and associated disorders

  2. Diabetes mellitus is associated with cerebral infarction in humans.

    “Studies utilising neuropathological data showed associations of diabetes and peripheral IR with brain infarcts”

    Review

    Review of Associations of Diabetes and Insulin Resistance With Brain Health in Three Harmonised Cohort Studies of Ageing and Dementia

    Diabetes/metabolism research and reviews

More on Diabetes mellitus

Low serum magnesium

upin humans1HR 1.4

1 study
  1. Low serum magnesium is associated with cerebral infarction in humans (Prior metabolic and bariatric surgery; low versus normal magnesium) (HR 1.40, 95% CI 1.05–1.86).

    “higher hazards of acute myocardial infarction (HR 1.77, 95% CI 1.24–2.53), cerebral infarction (HR 1.40, 95% CI 1.05–1.86)”

    HumansPrior metabolic and bariatric surgery; low versus normal magnesiumDay 90 through 3 years

    Low Serum Magnesium and Long-Term Mortality in Adults With Prior Metabolic and Bariatric Surgery: A Multicenter Propensity Score–Matched Cohort Study

    Frontiers in nutrition

More on Low serum magnesium

Obesity

downin humans1HR 0.891

1 study
  1. Obesity is associated with cerebral infarction in humans (Atrial fibrillation; BMI ≥30 versus BMI 19–24.9) (HR 0.891, 95% CI 0.869–0.915).

    “Obesity was associated with lower hazards of cerebral infarction (HR 0.891, 95% CI 0.869-0.915; p<0.001)”

    HumansAtrial fibrillation; BMI ≥30 versus BMI 19–24.9Mean follow-up 520–769 days across cohorts48.6% femalesn = 236,080

    Obesity linked to lower stroke risk in heart rhythm study

    AHA Scientific Sessions 2026 abstract

More on Obesity

Metabolic syndrome

upin humans1RR 1.85–1.96

1 study
  1. Metabolic syndrome is associated with cerebral infarction in humans (Metastatic hormone-sensitive prostate cancer; monotherapy and combination therapy groups) (RR 1.96 and 1.85 in monotherapy and combination therapy, respectively).

    “approximately twofold higher risks of myocardial infarction and cerebral infarction”

    HumansMetastatic hormone-sensitive prostate cancer; monotherapy and combination therapy groupsmales

    Pre-existing Metabolic Syndrome and Cardiometabolic Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study Using the TriNetX Network

    Clinical genitourinary cancer

More on Metabolic syndrome

Smoking

upin humans1OR 2.46

1 study
  1. Smoking is associated with cerebral infarction in humans (Prediagnostic smoking trajectories) (OR 2.46).

    “The strongest associations were observed for acute myocardial infarction (OR 3.51) and cerebral infarction (OR 2.46).”

    HumansPrediagnostic smoking trajectories

    Prediagnostic smoking intensity trajectories and subtype-specific vascular disease risk in a nationwide health screening population

    International journal of public health

More on Smoking

Comorbid depressive disorder and hypertension

upin humans1

1 study
  1. Cerebral infarction is associated with comorbid depressive disorder and hypertension in humans (patients with mental disorders).

    “Age 70~79 years, cerebral infarction, diabetes mellitus, and other factors increased the risk of comorbid depressive disorder and hypertension (P<0.05).”

    Humanspatients with mental disordersn = 890

    Comorbidity patterns and risk factors for mental disorders and physical diseases in older adults

    International Journal of Geriatrics

More on Comorbid depressive disorder and hypertension

All 52

Trial sponsors

Funding

5 grants since 2016

Japan Society for the Promotion of Science¥14.8MNational Heart, Lung, and Blood Institute$2.1M

Latest

Dec 2025: 18Jan 2026: 15Feb 2026: 13Mar 2026: 11Apr 2026: 7May 2026: 3Jun 2026: 8Jul 2026: 13Aug 2026: 7Sep 2026: 5Oct 2026: 16Nov 2026: 19135 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Obesity linked to lower stroke risk in heart rhythm study

Obesity was linked to a lower hazard of stroke from blocked blood flow—hazard ratio 0.891 versus normal weight—but higher heart failure hazards.Obesity was linked to a lower hazard of stroke from blocked blood flow—hazard ratio 0.891 versus normal weight—but higher heart failure hazards.

Cohort studyObesity
AHA Scientific Sessions 2026 Abstract

Add-ons linked to fewer strokes in treated hypertension with obesity

Stroke rates were 3.4% with one add-on drug class versus 4.0% with blood-pressure drugs alone; mean follow-up across comparisons ranged from 3.6–4.2 years.Stroke rates were 3.4% with one add-on drug class versus 4.0% with blood-pressure drugs alone; mean follow-up across comparisons ranged from 3.6–4.2 years.

Cohort studyObesity

See all 381 papers on cerebral infarction